<div id="readability-page-1"><p>Prime Medicine, Inc. (NYSE:PRME - Get Free Report) has been assigned a consensus rating of &#34;Moderate Buy&#34; from the eight analysts that are currently  covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one  has given a strong buy recommendation to  the company. The average 1 year price target among brokerages that have covered the stock in the last year is $9.2083.</p><ul><li>2 gene editing stocks to keep on your 2024 watchlist</li></ul><p>A number of brokerages have recently weighed in on PRME. Wedbush  restated an &#34;outperform&#34; rating and issued a $8.00 price target on shares of Prime Medicine in a research report on Monday, November 10th. Citigroup lowered their price objective on shares of Prime Medicine from $5.00 to $4.25 and set a &#34;neutral&#34; rating on the stock in a research note on Tuesday, November 11th. Finally, Chardan Capital dropped their target price on shares of Prime Medicine from $10.00 to $9.00 and set a &#34;buy&#34; rating for the company in a report on Monday, November 10th.</p><div><p><span></span><span>Get <strong>Prime Medicine</strong> alerts:</span></p></div><p><b>Read Our Latest Report on PRME</b></p><h2>Prime Medicine Price Performance</h2><p>NYSE PRME opened at $3.72 on Wednesday. The business has a 50 day moving average price of $4.92 and a 200 day moving average price of $3.65. The company has a market capitalization of $671.50 million, a P/E ratio of -1.81 and a beta of 2.64. Prime Medicine has a 1-year low of $1.11 and a 1-year high of $6.94. </p><h2>Institutional Investors Weigh In On Prime Medicine</h2><p>A number of institutional investors and hedge funds have recently bought and sold shares of PRME. Levin Capital Strategies L.P. raised its holdings in shares of  Prime Medicine by 300.0% in the second quarter. Levin Capital Strategies L.P. now owns 140,000 shares of the company's stock worth $346,000 after acquiring an additional 105,000 shares during the last quarter.  Palumbo Wealth Management LLC boosted its stake in shares of  Prime Medicine by 92.1% during the second quarter. Palumbo Wealth Management LLC now owns 183,358 shares of the company's stock valued at $453,000 after acquiring an additional 87,896 shares during the last quarter.  Vanguard Personalized Indexing Management LLC increased its position in  Prime Medicine by 52.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 23,191 shares of the company's stock worth $57,000 after purchasing an additional 7,954 shares in the last quarter.  Ieq Capital LLC purchased a new stake in  Prime Medicine during the 1st quarter worth about $69,000.  Finally, Bank of New York Mellon Corp raised its stake in  Prime Medicine by 20.4% in the 1st quarter. Bank of New York Mellon Corp now owns 155,992 shares of the company's stock valued at $310,000 after purchasing an additional 26,478 shares during the last quarter. Hedge funds and other institutional investors own  70.37% of the company's stock. </p><h2>About Prime Medicine</h2> (Get Free Report)<p>Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.</p><h2>See Also</h2><ul><li>Five stocks we like better than Prime Medicine</li><li>Profitably Trade Stocks at 52-Week Highs</li><li>Warner Bros. Sale Rumors Heat Up: What Investors Need to Know</li><li>Energy and Oil Stocks Explained</li><li>From Science Project to Solvent: WeRide’s 761% Revenue Surge</li><li>When to Sell a Stock for Profit or Loss</li><li>Will the S&amp;P 500 Rally in December? These 3 Signals Point to a Big Move Ahead</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBSTUU?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBSTUU"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2><p>Before you consider Prime Medicine, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PRME

<p>Prime Medicine, Inc. (NYSE:PRME) has received a consensus "Moderate Buy" rating from eight analysts. The stock has a 1-year price target average of $9.2083. Recent analyst actions include Wedbush's "outperform" rating with an $8 target, Citigroup's "neutral" rating with a $4.25 target, and Chardan Capital's "buy" rating with a $9 target. Institutional investors have increased their holdings, with hedge funds owning 70.37% of the stock. Prime Medicine focuses on genetic therapies using gene editing technology.</p>

Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts